Tharimmune Appoints New CMO, Board Member
Ticker: CNTN · Form: 8-K · Filed: Apr 10, 2025 · CIK: 1861657
| Field | Detail |
|---|---|
| Company | Tharimmune, INC. (CNTN) |
| Form Type | 8-K |
| Filed Date | Apr 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, appointment
TL;DR
Tharimmune brings in a new CMO and board member, potentially signaling a new phase for the company.
AI Summary
On April 9, 2025, Tharimmune, Inc. announced changes to its board of directors, including the appointment of Dr. Jonathan P. S. Farber as Chief Medical Officer and a new director. The company also disclosed compensatory arrangements for its officers.
Why It Matters
Changes in key leadership roles like Chief Medical Officer can signal shifts in the company's strategic direction and focus on research and development.
Risk Assessment
Risk Level: medium — Appointments of new officers and directors, especially in a biotech company, can introduce new strategic directions or potential integration challenges.
Key Players & Entities
- Tharimmune, Inc. (company) — Registrant
- Dr. Jonathan P. S. Farber (person) — Appointed Chief Medical Officer and Director
- 001-41210 (company) — Commission File Number
- 84-2642541 (company) — I. R. S. Employer Identification No.
FAQ
Who has been appointed as the new Chief Medical Officer for Tharimmune, Inc.?
Dr. Jonathan P. S. Farber has been appointed as the new Chief Medical Officer for Tharimmune, Inc.
What is Tharimmune, Inc.'s exact name as specified in its charter?
Tharimmune, Inc. is the exact name of the registrant as specified in its charter.
In which state was Tharimmune, Inc. incorporated?
Tharimmune, Inc. was incorporated in Delaware.
What is the Commission File Number for Tharimmune, Inc.?
The Commission File Number for Tharimmune, Inc. is 001-41210.
What is the business address of Tharimmune, Inc.?
The business address of Tharimmune, Inc. is 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 10, 2025 by Dr. Jonathan P. S. Farber regarding Tharimmune, Inc. (CNTN).